Table 2.

The MD Anderson resectability criteria for PDAC [1].

Factors	Potentially Resectable	Borderline Resectable	Unresectable
Tumor Anatomy (A)	No radiographic tumor interface with CA, SMA, or CHA No interface with SMV or PV or <180° interface without vein contour irregularity	Tumor-vessel circumferential interface <180° with SMA or CA Reconstructable short-segment interface with CHA Interface with SMV or PV >180° and/or reconstructable occlusion	>180° radiographic interface with CA or SMA Unreconstructable SMV or PV due to tumor involvement or occlusion
Tumor Biology (B)	No clear evidence of distant metastatic disease No evidence of regional lymphadenopathy CA 19-9 level normal or only mildly elevated	Imaging findings suggestive but not diagnostic of metastatic disease OR Confirmed regional lymphadenopathy OR CA 19-9 level moderately elevated	Confirmed extraregional lymphadenopathy
Patient Condition (C)	Good performance status (ECOG 0–1) No major comorbidities	Suboptimal performance status (ECOG 2–3) Multiple comorbidities with capacity for optimization and prehabilitation	Poor performance status (ECOG~3 or higher) Poor comorbidity profile with no capacity for optimization

ECOG, Eastern Cooperative Oncology Group.